The safety of IV pentamidine administered in an ambulatory setting

Chest

Volumn 110, Issue 1, 1996, Pages 136-140

  Yeung, Kam Tong ^b   Chan, Melinda ^b   Chan, Charles K N ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

Pneumocystis carinii pneumonia; prophylaxis; treatment

Indexed keywords

PENTAMIDINE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL ARTICLE; DAY CARE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPOGLYCEMIA; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; OUTPATIENT CARE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; AMBULATORY CARE; COST CONTROL; ECONOMICS; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMBULATORY CARE; COST SAVINGS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PENTAMIDINE; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES;

EID: 0029666326     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.1.136     Document Type: Article

References (12)

1. Conte JE Jr, Hollander H, Golden JA. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia: a pilot study. Ann Intern Med 1987; 107:495-98
2. Sands M, Kron MA, Brown RB. Pantamidine: a review. Rev Infect Dis 1985; 7:625-34
3. Centers for Disease Control. Guidelines for prophylaxis against P carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992; 41:1-10 (RH-4)
4. Lidman C, Tynall E, Berglund O, et al. Aerosolized pentamidine versus IV pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Infection 1993; 21:146-49
5. Ena J. Amador C, Pasquan F. et al. Once-a-month administration of intravenous pentamidine to patients infected with human immunodefieiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1994; 18:901-04
6. Pearson RD, Hewlett EL. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoa diseases. Ann Intern Med 1985; 103:782-86
7. Drake S, Lampasona V, Nicks HL, et al. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia, Clin Pharm 1985; 4:507-16
8. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105:37-44
9. Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1988; 109:280-87
10. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for P carinii pneumonia in patients with acquired immunodeficiency syndrome. Ann Intern Med 1994; 121:174-80
11. Andersen R, Boedicker M, Ma M, et al. Adverse reactions associated with pentamidine isethionate in AIDS patients: recommendations for monitoring therapy. Drug Intell Clin Pharm 1986; 20:862-68
12. Mallory DL, Parillo JE, Bailey KR, et al. Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. Crit Care Med 1987; 15:503-05